Xbrane Biopharma AB
Xbrane Biopharma AB, a pioneering biotechnology company headquartered in Sweden, focuses on the development of innovative biosimilars and biologics. Founded in 2006, Xbrane has made significant strides in the biopharmaceutical industry, particularly in the fields of ophthalmology and oncology.
The company is renowned for its flagship product, Xlucane, a biosimilar to Lucentis, which addresses serious eye diseases and showcases Xbrane's commitment to enhancing patient care through affordable treatment options. With a strong presence in Europe and expanding operations globally, Xbrane Biopharma has established itself as a key player in the biosimilar market, recognised for its rigorous development processes and high-quality standards.
As Xbrane continues to advance its pipeline, it remains dedicated to delivering innovative solutions that meet the evolving needs of healthcare providers and patients alike.
-9 vs industry average
Xbrane Biopharma AB’s score of 29 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Xbrane Biopharma AB?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Xbrane Biopharma AB's reported carbon emissions
In 2025, Xbrane Biopharma AB reported total emissions of approximately 3,000 kg CO2e, with Scope 2 emissions accounting for about 2,000 kg CO2e. The company has set ambitious climate commitments, aiming to reduce its Scope 2 emissions to near zero by 2025 and achieve a 50% reduction from a 2020 baseline by 2030. Additionally, Xbrane is targeting a near-zero reduction for its Scope 1 emissions by 2025. In 2023, the company reported Scope 2 emissions of approximately 8,000 kg CO2e, contributing to a combined Scope 1 and 2 total of about 9,000 kg CO2e. In 2022, Scope 2 emissions were approximately 10,000 kg CO2e, with no reported Scope 1 emissions during that year. Xbrane Biopharma AB's climate initiatives reflect a strong commitment to sustainability and reducing its carbon footprint, aligning with industry standards for climate action.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Xbrane Biopharma AB’s Climate Goals (2030 & 2050)
3 goals2030
50% reduction in Scope 2
Xbrane aims to reduce its Scope 2 emissions by 50% from 2020 baseline by 2030.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 3 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Xbrane Biopharma AB
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project